PriceTargets.com logo

Kazia Therapeutics - KZIA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 251.49%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.69 As of 10/30/2024 03:53 PM ET
▲ +0.3 (5.57%)

This chart shows the closing price for KZIA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kazia Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KZIA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KZIA

Analyst Price Target is $20.00
▲ +251.49% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Kazia Therapeutics in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 251.49% upside from the last price of $5.69.

This chart shows the closing price for KZIA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Kazia Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/11/2023HC WainwrightUpgradeNeutral ➝ Buy$20.00
8/2/2022Maxim GroupDowngradeBuy ➝ Hold
8/2/2022HC WainwrightDowngradeBuy ➝ Neutral
12/3/2021Maxim GroupReiterated RatingBuy$180.00
10/14/2021Maxim GroupInitiated CoverageBuy$180.00
1/5/2021HC WainwrightInitiated CoverageBuy$170.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Kazia Therapeutics logo
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.
Read More

Today's Range

Now: $5.69
Low: $5.16
High: $5.78

50 Day Range

MA: $4.06
Low: $3.20
High: $5.79

52 Week Range

Now: $5.69
Low: $1.87
High: $15.80

Volume

117,476 shs

Average Volume

450,594 shs

Market Capitalization

$92.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Kazia Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Kazia Therapeutics in the last twelve months: HC Wainwright.
View the latest analyst ratings for KZIA.

What is the current price target for Kazia Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Kazia Therapeutics in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 251.5%. HC Wainwright has the highest price target set, predicting KZIA will reach $20.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $20.00 for Kazia Therapeutics in the next year.
View the latest price targets for KZIA.

What is the current consensus analyst rating for Kazia Therapeutics?

Kazia Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KZIA will outperform the market and that investors should add to their positions of Kazia Therapeutics.
View the latest ratings for KZIA.

What other companies compete with Kazia Therapeutics?

Other companies that are similar to Kazia Therapeutics include Zevra Therapeutics, Amylyx Pharmaceuticals, YS Biopharma, Jasper Therapeutics and Lexeo Therapeutics. Learn More about companies similar to Kazia Therapeutics.

How do I contact Kazia Therapeutics' investor relations team?

Kazia Therapeutics' physical mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The company's listed phone number is (129) 472-4101 and its investor relations email address is [email protected]. The official website for Kazia Therapeutics is www.kaziatherapeutics.com. Learn More about contacing Kazia Therapeutics investor relations.